Literature DB >> 35417007

Cardiovascular and Metabolic Diagnoses Associated With Novel Hormonal Agents for Prostate Cancer in Nontrial Populations.

Nancy L Keating1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35417007      PMCID： PMC9360455          DOI： 10.1093/jnci/djac084

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   11.816


× No keyword cloud information.
  10 in total

1.  Secondary Prevention for Atherosclerotic Cardiovascular Disease: Comparing Recent US and European Guidelines on Dyslipidemia.

Authors:  Salim S Virani; Sidney C Smith; Neil J Stone; Scott M Grundy
Journal:  Circulation       Date:  2020-04-06       Impact factor: 29.690

2.  Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.

Authors:  Nancy L Keating; A James O'Malley; Stephen J Freedland; Matthew R Smith
Journal:  J Natl Cancer Inst       Date:  2009-12-07       Impact factor: 13.506

3.  Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.

Authors:  Nancy L Keating; A James O'Malley; Matthew R Smith
Journal:  J Clin Oncol       Date:  2006-09-20       Impact factor: 44.544

4.  Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.

Authors:  Glenn N Levine; Anthony V D'Amico; Peter Berger; Peter E Clark; Robert H Eckel; Nancy L Keating; Richard V Milani; Arthur I Sagalowsky; Matthew R Smith; Neil Zakai
Journal:  Circulation       Date:  2010-02-01       Impact factor: 29.690

5.  Comparative Cardiovascular Safety of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data.

Authors:  Jason Hu; Armen G Aprikian; Marie Vanhuyse; Alice Dragomir
Journal:  Clin Genitourin Cancer       Date:  2021-09-15       Impact factor: 2.872

6.  Risk of Metabolic and Cardiovascular Adverse Events With Abiraterone or Enzalutamide Among Men With Advanced Prostate Cancer.

Authors:  Lillian Y Lai; Mary K Oerline; Megan E V Caram; Phoebe A Tsao; Samuel R Kaufman; Brent K Hollenbeck; Vahakn B Shahinian
Journal:  J Natl Cancer Inst       Date:  2022-08-08       Impact factor: 11.816

7.  Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.

Authors:  Christopher S Saigal; John L Gore; Tracey L Krupski; Janet Hanley; Matthias Schonlau; Mark S Litwin
Journal:  Cancer       Date:  2007-10-01       Impact factor: 6.860

8.  The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer.

Authors:  Roberto Iacovelli; Chiara Ciccarese; Emilio Bria; Mario Romano; Emanuela Fantinel; Davide Bimbatti; Alessandro Muraglia; Antonio Benito Porcaro; Salvatore Siracusano; Matteo Brunelli; Renzo Mazzarotto; Walter Artibani; Giampaolo Tortora
Journal:  Clin Genitourin Cancer       Date:  2017-12-27       Impact factor: 2.872

Review 9.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Donna K Arnett; Roger S Blumenthal; Michelle A Albert; Andrew B Buroker; Zachary D Goldberger; Ellen J Hahn; Cheryl Dennison Himmelfarb; Amit Khera; Donald Lloyd-Jones; J William McEvoy; Erin D Michos; Michael D Miedema; Daniel Muñoz; Sidney C Smith; Salim S Virani; Kim A Williams; Joseph Yeboah; Boback Ziaeian
Journal:  Circulation       Date:  2019-03-17       Impact factor: 29.690

10.  Causes of Death Among Patients With Metastatic Prostate Cancer in the US From 2000 to 2016.

Authors:  Ahmed O Elmehrath; Ahmed M Afifi; Muneer J Al-Husseini; Anas M Saad; Nathaniel Wilson; Kyrillus S Shohdy; Patrick Pilie; Mohamad Bassam Sonbol; Omar Alhalabi
Journal:  JAMA Netw Open       Date:  2021-08-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.